Фармакокинетические свойства Максаквина

1. Структура и антибактериальная активность максаквина / / Пульмонология.— 1993.— Приложение 1.

2. Yamasaki F .t Suzuki Y., Uno К. Pharmacokinetic and clinical studies on N Y -198 / / Chem otherapy (Tokyo).— 1988.— Vol.36, Suppl.2.— P .625— 629.

3. Okezciki E .t Makino E ., Ohmichi K . et al. Disposition and metabolism of NY-198. II. I-IPLS and bioassay studies of absorbsion and excretion in the dog / / Ibid.— P. 138— 143.

4. Chang М ., Kozobud L., Schoenhard G. et al. The development of a high thoughput totally autom ated assay for SC -47111, a new quinolone antibacterial agent / / Adv. Lab. Automat. Robotics.— 1989.— Vol.5 .— P .433— 440.

5. Morrison P .J ., Mant T .G .K ., Norman G .T . e t al.. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses / / Antimicrob. Agents Chemother.— 1988.— V ol.32.— P .1503— 1507.

6. Stone J.W .,, Andrews J.M . Ashby J.P. et al. Pharmacokinetics and tissue penetration of orally adm inistered lomefloxacin / / Ibid.— P .1508— 1510.

7. Kavi J., Slone J., A ndrews J.M . et al. Tissue penetration and pharm acokinetics of lomefloxacin following multiple doses / / Eur. J. Clin. Microbiol. Infect. Dis.— 1989.— Vol.8.— P. 168— 170.

8. Hunt T .L ., Adams M .A . Pharmacokinetics and safety of lomefloxacin following multiple doses / / Diagn. Microbiol. Infect. Dis.— 1989.— V ol.12.— P .181 — 187.

9. Mant T.G .K. Multiple-dose pharmacokinetics of lomefloxacin rationale for once-a-dav dosing / / Am. J. M ed.— 1992.— Vol.92, Suppl.4A .— P .2 6 S — 32S.

10. Morse I.S . Pharmocokinetics and safety of single oral doses of lomefloxacin / / Biopharm . Drug. Dispos.— 1990.— V o l.ll.— P .5 4 3 — 551.

11. Gros I., Carbon C. Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days / / Antimicrob. Agents Chemother.— 1990.— Vol.34.— P .150— 152.

12. Kurkem yerJ., Lima J., Adams M .t Hunt T. Lomefloxacin pharm acokinetics: binding to plasma proteins and the effect of food on absorption / / Program and Abstracts of the TwentyNinth Interscience Conference on Antimicrobial Agents and Chemotherapy .— Washington : American Societyfor Microbiology, 1989.— P .3 1 7 .— A bstract 1275.

13. Hooper W.D., Dickenson R .G ., Eadie M .J. Effect of food on absorption of lomefloxacin / / Antimicrob. Agents Chemother.— 1990.— Vol.34. — P .1797— 1799.

14. Hoffken G., Dorner K ., Glatzel P.O. et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids / / Eur. J. Clin. Microbiol.— 1985.— V ol.4.— P .345.

15. Frost R .W ., Lettieri J.T ., Noe A. et al. Effect of aluminium hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Abstract P IIIC -6 / / Clin. Pharm acol. Ther.— 1989.— Vol.45.— P .165.

16. Badian M ., Eckert II.G ., Malerczyk V. et al. Influence of antacids as concom itant medication on ofloxacin pharm acokinetics in healthy volunteers / / Eur. J.' Clin. Pharmacol.— 1989.— Vol.36, S uppl.— Abstract 11.35.

17. Graselci T .II.Jr., Schentag J.J., Seelman A .J. et al. Inhibition of enoxacin absorption by antacids or ranitidine / / Antimicrob. Agents Chemother.— 1989.— V ol.33.— P .615— 617.

18. Parpia S .II., N ix D .E., Hejmanowski L.G. et al. Sucralfate reduces the gastrointestinal absorption of norfloxacin / / Ibid.— P .9 9 — 102.

19. Ryerson B ., Toothaker R ., Schleyer I. et al. Effect of sucralfate on enoxacin pharm acokinetics / / Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy .— Washington: American Society for Microbiology, 1989.— P. 136.— Abstract 214.

20. Garrelts J.C ., Godley P .J., P eterie J.D. et al. Sucralfate significantly reduces ciprofloxacin concentrations in serum / / Antimicrob. Agents Chemother.— 1990.— Vol.3 4.— P .931 — 933.

21. Kunka R .E , Wong Y.Y., Lyon J.L. Effect of antacid on the pharm acokinetics of lomefloxacin. Abstract P P 1267 / / Pharm . Res.— 1988.— Vol.5, Suppl.— P.S165.

22. Foster T. The effect of antacid timing on lomefloxacin bioavailability / / Pharmacotherapy.— 1991.— Vol.l 1.— P. 101.

23. Nix D., Sc/ientag J. Lomefloxacin absorpition kinetics when administered with ranitidine and sucralfate / / Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy.— Washington: American Society for Microbiology, 1989.— P .317.— Abstract 1276.

24. Lebscick M ., Nix D., Schentag J. et al. Impact of gastric pH on ranitidine-cnoxacin drug-drug interaction. Abstract 128 / / J. Clin. Pharmacol.— 1988.— V ol.28.— P .939.

25. Okezaki E ., Terasaki T., Nakcnnura M. et al. Serum protein binding of lomefloxacin, a new antimicrobial agent, and its related quinolones / / J. Pharm . Sci.— 1989.— Vol.7 8.— P .504— 507.

26. Baldwin D .R ., Iloneybourne D ., Andrews J .M . et a l. Concentrations of oral lomefloxacin in serum and bronchial mucosa / / Antimicrob. Agents Chem other.— 1990.— Vol.34.— P .1017— 1019.

27. Bergogne-Bcrezin E ., Muller-Serieys C., Kafee H. Penetration of lomefloxacin into bronchial secretions following single and multiple oral administration / / Am. J. Med.— 1992.— Vol.92, Suppl.4A .— P .8S— 1 IS.

28. Loos U., Sorgel F .t M uth P. et al. Pulmonary disposition of lomefloxacin / / Program and Abstracts of the Twenty-N inth Interscience Conferenceon Antimicrobial Agents and Chemotherapy .— Washington : American Societyfor Microbiology, 1989.— P .3 1 7 .— Abstract 1272.

29. Kovarik J .M ., Smit J ., Sips D .J. et a l. Steady state pharmacokinetics and sputum penetration of lomefloxacin in chronic bronchitis patients / / Program and Abstracts of the 30th Intersciencc Conferenceon Antimicrobial Agents and Chemotherapy .— Washington : American Societyfor Microbiology, 1990.— P .253.— Abstract 1005.

30. Sorgel F., Jaehde U., N aber K., Stephan U. Pharm acokinetic disposition of quinolones in hum an body fluids and tissues / / Clin. Pharm ocokinet.— 1989.— Vol. 16, Suppl.l.— P .5 — 24.

31. Leroy A ., Humbert G., Fillastre J.-P ., Grise P. Penetration of lomefloxacin into hum an prostatic tissue / / Am. J. M ed.— 1992.— Vol.92, Suppl.4A .— P .12S — 14S.

32. Kovarik J.M ., de Hond J.A .P .M ., Hoepelm an I.M . et al. Intraproslatic distribution of lomefloxacin following mulliple-dose adm inistration / / Antimicrob. Agents Chem other.— 1990.— Vol.34.— P .2398— 2401.

33. On A ., N ightingale C .IL , Quintifiani R. et al. Lomefloxacin concentrations in bone after a single oral dose / / Am. J. Med.— 1992.— Vol.92, Suppl.4A .— P.15S— 17S.

34. Carlier M .B ., Tulkens P.M . Uptake and subcellular localization of lomefloxacin (SC -47111) in phagocytic cells in comparison with pefloxacin and fleroxacin / / Program and Abstracts of the Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy .— W ashington: Am erican Society for Microbiology, 1988.— P .l 19.— Abstract 52.

35. Perea E .J., Garcia I., Pascual A. Comparative penetration of lomefloxacin and other quinolones into human phagocytes / / Am. J. M ed.— 1992.— Vol.92, Suppl.4A .— P .48S— 51S.

36. Klimberg I. IV., C hilds S.J, Madore R.J., Klimberg S.R. Amulticenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery / / Ibid.— P.121S — 125S.

37. Pascual. A ., Garcia I., Perea E .J. Entry of lomefloxacin and tem afloxacin into hum an neutrophils, peritoneal macrophages and tissue culture cells / / Diagn. Microbiol. Infect. Dis.— 1992.— V ol.15.— P .393— 398.

38. Baldwin D .R., Wise R. Andrews J.M . et al. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral adm inistration / / Br. J. Clin. Pharmacol.— 1993.— In press.

39. Nacashim a M ., Uematsu T., Takiguchi Y. et al. Phase I study on N Y -198 / / Chem otherapy (Tokyo).— 1988.— Vol.36, Suppl.2.— P .2 0 1 — 239.

40. Leroy A., Fillastre J.P., Humbert G. Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function / / Antimicrob. Agents Chemother.— 1990.— Vol.34.— P. 17— 20.

41. Kaji M ., Saito A ., Shimada J. et al. Clinical studies on NY-198 / / Chem otherapy (Tokyo).— 1988.— V ol.36, Suppl.2.— P .5 1 3 — 526.

42. Blum R .A ., Schultz R .W ., Schentag J.J. Pharm acokinetics of lomefloxacin in renally compromised patients / / Antimicrob. Agents Chemother.— i 990.— Vol.34.— P .2364— 2368.

43. Nilsen O.G., Saftved t E ., Walstad R .A ., Marstein S. Single-dose pharm acokinetics of lomefloxacin in patients with normal and impaired renal function / / Am. J. M ed.— 1992.— Vol.92, Suppl.4A .— P .3 8 S — 40S.

44. Lebrec D., Gaud in C., Benhamou J.-P. Pharmocokinetics of lomefloxacin in patients with cirrhosis / / Ibid.— P .4 1 S — 44S.

45. Woodworth J., F itzsimmons S. Lomefloxacin pharmacokinetics in young and elderly subjects / / Program and A bstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy .— Washington: American Society for Microbiology, 1989.— P .316.— Abstract 1268.

46. Crome P., Morrison P.J. Pharmacokinetics of a single oral dose of lomefloxacin in healthy elderly volunteers / / D rug Invest.— 1991.— Vol.3.— P .183— 187.

47. Schentag J.J., Goss T.F. Quinolonc pharmocokinetics in the elderly / / Am. J. M ed.— 1992.— Vol.92, Suppl.4A.— P.33S— 37S.

48. K ovarik J.M ., H oepelm an A .I.M ., S m it J.M . et al. Steady-state pharm acokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections / / Antimicrob. Agents Chemother.— 1992.— Vol.36.— P .2458— 2461.

49. Wijnands W .J.A., Vree T.B ., van Ilerwaarden C .E A . The influence of quinolonc derivatives on theophylline clearance / / Br. J. Clin. Pharmacol.— 1986.— Vol.22.— P .677— 683.

50. Schwartz J., Jauregui E , Lettieri J., Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady -state concentrations in scrum / / Antimicrob. Agents Chemother.— 1988.— Vol.3 2.— P .7 5 — 77.

51. Nix D .E ., DeVito J.M ., Whitbread M .A ., Schentag J.J. Effect of multiple dose oral ciprofloxacin on the pharmacokinetics theophylline and indocvanine green / / J. Antimicrob. Chemother.— 1987.— Vof.19.— P .2 6 3 — 269.

52. Wijnands W .J.A ., Vree T.B ., Baars A .M ., van Herwaarden C .E A . Steady -state kinetics of the quinolone derivatives ofloxacin, enoxacin , ciprofloxacin and pefloxacin during maintenance treatment with theophylline / / Drugs.— 1987.— Vol.34, Suppl.l.— P .159— 169.

53. Davis R .L ., Kelly II. W .,Quenzer R. W. et al. Effect of norfloxacin on the theophylline metabolism / / Antimicrob. Agents Chemother.— 1989.— V ol.33.— P .2 1 2 — 214.

54. Ho G., Tierney M .G ., Dales R .E . Evaluation of the effect of norfloxacin on the pharmocokinetics of theophylline / / Clin. Pharmacol. Ther.— 1988. — Vol.44.— P .35— 38.

55. Staib A .II., IlarderS., Mieke S. et al. Gyrase-inhibitors impair caffeine elemination in man / / Methods Find. Exp. Clin. Pharmacol.— 1987.— Vol.9.— P .l 93— 198.

56. Harder S., Staib A .II., Beer C. et al. 4-Quinolones inhibit biotransformation of caffeine / / E ur. J. Clin. Pharmacol.— 1988.— Vol.3 5.— P .651— 656.

57. Parent M ., LcBel. M . Meta-analysis of quinolone-thcophylline interaction / / D IC P Ann. Pharmacother.— 1991.— Vol.2 5.— P .191 — 194.

58. Ilealy D.P., P olkR.E., Kanawati L et al. Interaction between oral ciprofloxacin and cafeine in normal volunteers / / Antimicrob. Agents Chemother.— 1989.— Vol.33.— P .4 7 4 — 478.

59. Nix D .E., Norm an A ., Schentag J.J. Effect of lomefloxacin on the theophylline pharmocokinetics / / Ibid.— P. 1006— 1008.

60. Staib A .II., Harder S., Fuhr U., Wack C. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid 11 Int. J. Clin. Pharmacol. Ther. Toxicol.— 1989.— Vol.27.— P.289— 293.

61. Kuzuva T., Takagi K , Apichartpichcan R. et al. Kinenetic interaction between theophylline and a newly developed quinolone, IIY — 198 / / J. Pharmacobio -Dyn .— 1989.— V ol.12.— P .4 0 5 — 409.

62. Robson R.A., BeggE.J., Atkinson II.C. et al. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline / / Br.J. Clin. Pharmacol.— 1990.— Vol.29.— P .491— 493.

63. LeBel M ., Vallee F., St-Lciurent M . Influence of lomefloxacin on the pharm acokinetics of theophylline / / Antimicrob. Agents Chemother.— 1990.— V ol.34.— P .1254— 1256.

64. Wijnands G.J.A., Cornel J.IL , Martea L., Vrce T.D. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man / / Chest.— 1990.— V ol.98.— P. 1440— 1444.

65. Healy D.P., Sc/ioenle J.R ., Stotka J., Polk R.E. Lack of interaction between lomefloxacin and caffeine in normal volunteers / / Antimicrob. Agents Chemother.— 1991.— Vol.35.— P .660— 664.

66. Fuhr U., Anders E .-M ., Mohr G. et al. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA 2 activity in vivo and in vitro / / Ibid.— 1992.— Vol.36.— P .942— 948.

67. Winn M .J., Kifiering/iam N .R ., Coleman M .D. et al. The effects of lomefloxacin on cytochrome P-450 mediated drug metabolism in human liver microsomes / / Br. J. Clin. Pharmacol.— 1989. — Vol.28, Suppl.— P .238— 239.

68. Stratton C.IT., Weeks L.S. Bactericidal activity of lomefloxacin SC -47111 (NY -198) and ciprofloxacin against selected pathogens / / Diagn. Microbiol. Infect. D is.— 1989.— Vol. 12, Suppl.3.— P.29S— 34S.

69. Fernandes P .P ., Swanson R .N . Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies / / Drugs Exp. Clin. Res.— 1988.— V ol.14.— P .375— 378.

70. Lode II., Hoffken G ., Doeckk M . et al. Comparative fluoroquinolne pharmacokinetics and metabolism / / Ciprofloxacin in Clinical Practice: New Light on Established and Emerging Uses / Ed. I I.Lode.— Stuttgart: Schwer Verlag GmbH, 1990.— P .2 1 — 31.

71. Ciprofloxacin Product Information M onograph— Compendium of Preclinical and Clinical D ata.— New York: Marcnel Dekker, 1988.

72. Nix D .E., Watson W .A., Lener M .E . et al. Effect of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin / / Clin. Pharmacol. Ther.— 1989.— Vol.46.— P.700— 705.